We hope that your organization will consider signing the attached letter to the House and Senate Judiciary Committees expressing support for balanced patent reform that strengthens the current system.
A number of bills have recently been introduced in Congress to make updates to the U.S. patent system. As you well know, patents are the lifeblood of the biopharmaceutical industry and critical to the advancement of new treatments. Securing a strong and reliable patent for an innovative idea spurs investment which turns that idea into a novel product. The value of the patent is what attracts investment and keeps the idea progressing through the stages of research and development.
The attached letter focuses on the importance of patents as a driver for innovation. One area of particular concern to our industry is the U.S. Patent and Trademark Office’s (PTO) Inter Partes Review (IPR) process. Congress created the IPR process in 2011 as an alternative patent challenge system designed to provide a faster and more cost-effective alternative to litigation. Unfortunately, this new system allows for a lesser standard than the courts which makes it easier to invalidate patents. We are concerned about the impact this will have on the value of patents, and ultimately, investment in new treatments for patients.
The attached letter asks that Congress maintain a strong and secure patent system, and address abuses that have emerged at the PTO. With Congress moving quickly to advance comprehensive patent reform, the deadline to sign is Tuesday, May 12, 2015. If this is also a priority for your organization, we hope that you will consider joining the letter. Please contact Lauren Neff (firstname.lastname@example.org) directly if your organization would like to lend its name to this important effort.
We sincerely appreciate your interest in this issue and your consideration of this request. As always, please do not hesitate to contact us any time with questions.